Vontobel Holding Ltd. raised its stake in shares of Certara, Inc. (NASDAQ:CERT – Free Report) by 104.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,810 shares of the company’s stock after buying an additional 12,656 shares during the period. Vontobel Holding Ltd.’s holdings in Certara were worth $452,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of CERT. American Trust acquired a new stake in Certara during the first quarter worth about $347,000. US Bancorp DE raised its position in Certara by 2.8% in the 1st quarter. US Bancorp DE now owns 23,827 shares of the company’s stock worth $574,000 after purchasing an additional 640 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Certara by 33.3% during the 1st quarter. Russell Investments Group Ltd. now owns 119,879 shares of the company’s stock valued at $2,871,000 after acquiring an additional 29,938 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Certara by 68.9% in the 1st quarter. SG Americas Securities LLC now owns 14,329 shares of the company’s stock valued at $345,000 after buying an additional 5,845 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund bought a new position in Certara during the 1st quarter worth about $788,000. 67.26% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In related news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $14.60, for a total value of $747,870.40. Following the completion of the transaction, the insider now directly owns 128,883 shares of the company’s stock, valued at approximately $1,881,691.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.60% of the stock is currently owned by insiders.
Certara Price Performance
Certara (NASDAQ:CERT – Get Free Report) last announced its quarterly earnings data on Wednesday, August 9th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.02. Certara had a net margin of 5.45% and a return on equity of 5.56%. The firm had revenue of $90.45 million for the quarter, compared to analyst estimates of $92.04 million. On average, analysts expect that Certara, Inc. will post 0.33 earnings per share for the current year.
Analysts Set New Price Targets
A number of equities analysts recently commented on the company. Stephens reiterated an “overweight” rating and set a $20.00 price target on shares of Certara in a report on Wednesday. Barclays lowered their price objective on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, August 11th. Credit Suisse Group decreased their target price on shares of Certara from $27.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, August 10th. Jefferies Financial Group cut shares of Certara from a “buy” rating to a “hold” rating and decreased their target price for the stock from $24.50 to $17.00 in a research note on Tuesday, August 22nd. Finally, William Blair cut shares of Certara from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 10th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Certara currently has a consensus rating of “Hold” and a consensus price target of $19.71.
Check Out Our Latest Research Report on Certara
Certara Profile
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.
Further Reading
- Five stocks we like better than Certara
- When to Sell a Stock for Profit or Loss
- MarketBeat Week in Review – 10/9 – 10/13
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- What BlackRock’s Earnings Tell You About The Stock Market Tide
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Sociedad Quimica y Minera de Chile Well Positioned Lithium Stock
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.
